U.S. scientists say a gene related to brain development and function may play a casual role in schizophrenia development.
Schizophrenia is known to be associated with changes in myelin, which is formed around nerve fibers by a group of central nervous cells called oligodendrocytes, which are regulated by the gene oligodendrocyte lineage transcription factor 2, or OLIG2.
Professor Joseph Buxbaum and colleagues at the Mount Sinai School of Medicine collaborated with the United Kingdom's Cardiff University School of Medicine to analyze DNA in blood samples from 673 unrelated patients with schizophrenia and compared their genetic information to 716 patients who did not have the disease.
The study showed variation in OLIG2 was associated with schizophrenia. OLIG2 also showed a genetic association with schizophrenia when examined together with two other genes -- CNP and ERBB4 -- which are also active in myelin development.
"Multiple genes likely have a role in schizophrenia and there are probably many things happening in the brain of a schizophrenia patient," Buxbaum said. "The findings from this study help us tease out a potential biological cause that may be contributing to this debilitating illness."
The research appears in the Proceedings of National Academy of Sciences.
Copyright 2006 by United Press International
Related stories:
Researchers piece together gene 'network' linked to schizophrenia
Reporting this week in the Archives of General Psychiatry, researchers at the Johns Hopkins University School of Medicine have uncovered for the first time molecular circuitry associated with schizophrenia that links three previously known, yet unrelated proteins.
New schizophrenia genes uncovered
(PhysOrg.com) -- Researchers have discovered new genes linked to schizophrenia, it has been revealed. In two papers published in
Nature today (July 30), scientists identify four mutated gene regions that may hold the key to producing new tailor-made drugs to treat the devastating mental illness.
Protein on 'speed' linked to ADHD
A genetic change in the dopamine transporter – one of the brain's dopamine-handling proteins – makes it behave as if amphetamine is present and "run backward," Vanderbilt University Medical Center investigators report this week in
The Journal of Neuroscience.
Researchers Pinpoint Gene Mutations Responsible for 10 Percent of Schizophrenia
Scans of the genome of patients with schizophrenia have revealed rare spontaneous copy number mutations that account for at least 10 percent of the non-familial cases of the disease. Researchers describe specific genetic mutations present in individuals who have schizophrenia, but not present in their biological parents who do not have the disease.
A new gene trigger for pregnancy disorder identified
The COMT gene – known already for its role in schizophrenia – has been found to play a role in preeclampsia, according to a report in today’s advance on-line issue of
Nature.
Scientists dig deeper into the genetics of schizophrenia by evaluating microRNAs
Researchers at Columbia University Medical Center have illuminated a window into how abnormalities in microRNAs, a family of molecules that regulate expression of numerous genes, may contribute to the behavioral and neuronal deficits associated with schizophrenia and possibly other brain disorders.
Human brain appears 'hard-wired' for hierarchy
Human imaging studies have for the first time identified brain circuitry associated with social status, according to researchers at the National Institute of Mental Health (NIMH) of the National Institutes of Health. They found that different brain areas are activated when a person moves up or down in a pecking order – or simply views perceived social superiors or inferiors. Circuitry activated by important events responded to a potential change in hierarchical status as much as it did to winning money.
Concentrating on different aspects of pain leads to breakthrough in migraine genetics
Migraine is the most common cause of episodic headache, and by far the most common neurological cause of a doctor’s visit. It affects some 15% of the population, including some 41 million people in Europe, and places a considerable burden on healthcare in both the developed and the developing world.